Summary
In a clinical study of high-dose thymidine (TdR) treatment, toxic effects, TdR metabolism, and the influence of TdR on pyrimidine and purine metabolism were examined. Ten patients with solid tumors were treated with continuous infusion of TdR at 34–75 g/m2/day for 3 to 5 days. Hematologic toxicity occurred with 5-day TdR infusion at 75 g/m2/day but not when plasma TdR concentration failed to reach millimolar levels. In three patients who received similar TdR doses, plasma TdR levels were related to elimination rates of TdR and its metabolites from plasma. In one patient in whom urinary excretion was studied, 100% of the TdR dose given was recovered in the form of TdR, thymine (Thy), β-aminoisobutyrate, and 5-hydroxymethyluracil (5-HMUra). The latter metabolite, which had not been previously described in high-dose TdR treatment, was also found in plasma at levels from 5% to 10% of those of TdR. No effects of high-dose TdR infusion on purine levels in plasma were observed, while a substantial increase in uracil levels was noted both in plasma and urine. These data provide further information on high-dose TdR treatment with regard to clinical, pharmacokinetic, and biochemical effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bruno S, Postes DS, Bono VH, Jr, Macdonald JS, Kubota TT (1981) “High-dose thymidine in clinical oncology. Cancer Treat Rep 65:57–63
Chiuten DF, Wiernik PH, Zaharko DS, Edwards L (1980) Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion. Cancer Res 40:818–822
Egan EM, Sargent L, Rosowsky A, Kufe DW (1981) Rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of deoxycytidine. Cancer Treat Rep 65:853
Fink K, Cline RE, Henderson RD, Fink RM (1956) Metabolism of thymine (methyl-C14 or-2-C14) by rat liverin vitro. J Biol Chem 221:425–433
Kirkwood JM, Ensminger WD, Rosowsky A, Papathanasopoulos N, Frei E III (1980) Comparison of pharmacokinetics of 5-fluorouracil with concurrent thymidine infusions in a phase I trial. Cancer Res 40:107–113
Khym JX (1975) Analytical system for separation of tissue nucleotides at low pressure on conventional anion exchanger. Clin Chem 21:1245–1252
Leyva A, Schornagel JH, Pinedo HM (1980) High performance liquid chromatography of plasma pyrimidines and purines in cancer chemotherapy. Adv Exp Med Biol 122B:389–394
Martin DS, Stolfi RL, Sawyer RC, Nayak R, Spiegelman S, Young CW, Woodcock T (1980) An overwiew of thymidine. Cancer 45:1117–1128
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Ohnuma T, Roboz J, Waxman S, Mandel E, Martin DS, Holland JF (1980) Clinical pharmacological effects of thymidine plus 5-FU. Cancer Treat Rep 64:1169–1177
Schornagel JH, Leyva, Pinedo HM (1982) Is there a role for thymidine in cancer chemotherapy? Cancer Treat Rev 9:331–352
Van Gennip AH (1981) Screening for disorders of purine and pyrimidine metabolism. Doctoral thesis, State University, Utrecht, The Netherlands
Van Gennip AH, Van Bree-Blom EJ, Grift J, de Bree PK, Wadman SK (1980) Urinary purines and pyrimidines in patients with hyperammonemia of various origins. Clin Chim Acta 104:227–233
Wadman SK, Beemer FA, De Bree PK, Duran M, Van Gennip AH, Retting D, Van Sprang FJ (1983) New defects of pyrimidine metabolism. Adv Exp Med Biol (in press)
Zaharko DS, Bolten BJ, Chiuten D, Wiernik PH (1979) Pharmacokinetic studies during phase I trials of high-dose thymidine infusions. Cancer Res 39:4777–4781
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leyva, A., Schornagel, J.H., Kraal, I. et al. Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors. J Cancer Res Clin Oncol 107, 211–216 (1984). https://doi.org/10.1007/BF01032609
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01032609